C
Constanze Voigtländer
Researcher at University of Erlangen-Nuremberg
Publications - 6
Citations - 961
Constanze Voigtländer is an academic researcher from University of Erlangen-Nuremberg. The author has contributed to research in topics: Immune tolerance & Cytokine. The author has an hindex of 5, co-authored 6 publications receiving 932 citations.
Papers
More filters
Journal ArticleDOI
Repetitive Injections of Dendritic Cells Matured with Tumor Necrosis Factor α Induce Antigen-specific Protection of Mice from Autoimmunity
Mauritius Menges,Susanne Rößner,Constanze Voigtländer,Heike Schindler,Nicole A. Kukutsch,Christian Bogdan,Klaus J. Erb,Gerold Schuler,Manfred B. Lutz +8 more
TL;DR: It is described that stimulation by TNF-α results in incompletely matured DCs (semi-mature DCs) which induce peptide-specific IL-10–producing T cells in vivo and prevent EAE.
Journal ArticleDOI
Myeloid dendritic cell precursors generated from bone marrow suppress T cell responses via cell contact and nitric oxide production in vitro
Susanne Rössner,Constanze Voigtländer,Carsten Wiethe,Jens Hänig,Christian Seifarth,Manfred B. Lutz +5 more
TL;DR: The generation of MSC is described as myeloid DC precursors with potent suppressive activity on allogeneic and OVA‐specific CD4+ and CD8+ T cell responses in vitro preceding their development into immature DC.
Journal ArticleDOI
Dendritic Cells Matured With TNF can be Further Activated In Vitro and After Subcutaneous Injection In Vivo Which Converts Their Tolerogenicity Into Immunogenicity
Constanze Voigtländer,Susanne Rössner,Eva Cierpka,Gabi Theiner,Carsten Wiethe,Mauritius Menges,Gerold Schuler,Manfred B. Lutz +7 more
TL;DR: It is shown that TNF/DC are not terminally differentiated but can still respond to the microbial stimulus lipopolysaccharide, which is important for selecting the appropriate injection route of human DC for tumor immunotherapy.
Journal ArticleDOI
Infliximab (Anti–Tumor Necrosis Factor α Antibody): A Novel, Highly Effective Treatment of Recalcitrant Subcorneal Pustular Dermatosis (Sneddon-Wilkinson Disease)
TL;DR: A 79-year old woman presented with a 7-year history of subcorneal pustular dermatosis (SPD), which was resistant to multiple therapeutic trials including colchicine, retinoids, systemic glucocorticosteroids, UV phototherapy, azathioprine, and azulfidine.
Journal ArticleDOI
Cutting Edge: Resistance to Apoptosis and Continuous Proliferation of Dendritic Cells Deficient for TNF Receptor-1
Jens Oliver Funk,Henning Walczak,Constanze Voigtländer,Susanne Berchtold,Thomas Baumeister,Pia Rauch,Susanne Rössner,Alexander Steinkasserer,Gerold Schuler,Manfred B. Lutz +9 more
TL;DR: Prolonged survival of TNFR1−/− DC appears to be independent from NF-κB and Bcl-2 pathways and is rather enabled by the down-regulation of CD95, resulting in the resistance to CD95 ligand-induced apoptosis.